特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
950108

代謝障害治療薬の世界市場:業界の分析、市場規模、シェア、成長性、 動向、予測:2019年~2026年

Global Metabolic Disorder Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2019 to 2026

出版日: | 発行: Value Market Research | ページ情報: 英文 175 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
代謝障害治療薬の世界市場:業界の分析、市場規模、シェア、成長性、 動向、予測:2019年~2026年
出版日: 2020年07月01日
発行: Value Market Research
ページ情報: 英文 175 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、世界の代謝障害治療薬市場を調査したもので、業界やバリューチェーンの分析、製品別、疾患別、地域別の分析、競合情勢、企業プロファイルなどの情報を提供するととともに、新型コロナウイルス感染症(COVID-19)パンデミックの影響についても分析しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 業界分析

  • イントロダクション
  • 成長促進要因
  • 成長阻害要因
  • 市場機会
  • 市場の動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーンの分析

  • バリューチェーン分析
  • 原材料分析
  • 潜在的なバイヤーのリスト
  • マーケティングチャネル

第5章 製品別の市場分析

  • 市場の概要
  • 市場分析
  • 異染性白質ジストロフィーの市場分析
  • グロボイド白質ジストロフィー
  • 肝性脳症
  • その他

第6章 疾患別の市場分析

  • 市場の概要
  • 市場分析
  • 糖尿病
  • 肥満
  • 高コレステロール血症
  • リソソーム蓄積症

第7章 地域別の市場分析

  • 地域の展望
  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 競合情勢
  • 提携/協力/契約
  • 合併と買収
  • 新製品の発売
  • その他の動き

第9章 企業プロファイル

  • 会社シェア分析
  • 市場集中率
  • AbbVie Inc.
  • Actelion Pharmaceuticals Ltd.
  • AstraZeneca
  • Biocon
  • Boehringer Ingelheim
  • CymaBay Therapeutics
  • Eli Lilly and Company
  • Merck KgaA
  • Novo Nordisk
  • Sanofi

第10章 COVID-19パンデミックの影響分析

  • 市場における影響の分析
  • 生産、輸入、輸出、需要への影響分析
  • COVID-19パンデミック前と後の市場
  • 2020年の市場に対する影響のシナリオ別推定
  • 市場のミクロ因子とマクロ因子の分析
図表

LIST OF TABLES

  • Global Market Snapshot
  • Drivers of the Global Market Impact Analysis
  • Restraints of the Global Market Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • COVID-19 Impact Analysis by Production, Import, Export and Demand
  • Pre V/S Post COVID-19 Market
  • Estimated Impact Of The Coronavirus (Covid-19) Epidemic On The Market Size In 2020, By Scenario
  • COVID-19: Micro and Macro Factor Analysis on the Market
  • Global Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Metachromatic Leukodystrophy by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Globoid Leukodystrophy by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Hepatic Encephalopathy by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Others by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis by By Disease (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Diabetes by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Obesity by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Hypercholesterolemia by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Lysosomal Storage Diseases by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market by Geography (USD MN)
  • North America Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • North America Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • North America Metabolic Disorder Therapeutics Market Estimate by Country (USD MN)
  • United State Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • United State Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Rest of North America Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Rest of North America Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Europe Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Europe Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • United Kingdom Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • United Kingdom Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • France Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • France Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Germany Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Germany Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Rest of Europe Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Rest of Europe Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Asia Pacific Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Asia Pacific Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Asia Pacific Metabolic Disorder Therapeutics Market Estimate by Country (USD MN)
  • China Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • China Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Japan Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Japan Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • India Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • India Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Rest of Asia Pacific Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Rest of Asia Pacific Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Latin America Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Latin America Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Latin America Metabolic Disorder Therapeutics Market Estimate by Country (USD MN)
  • Brazil Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Brazil Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Rest of Latin America Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Rest of Latin America Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Middle East & Africa Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Middle East & Africa Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Middle East & Africa Metabolic Disorder Therapeutics Market Estimate by Country (USD MN)
  • Middle East Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Middle East Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Africa Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Africa Metabolic Disorder Therapeutics Market Estimate by By Disease (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisiton
  • New Product Launch
  • Other Developments
  • Company Market Share Analysis, 2019

LIST OF FIGURES

  • Research Scope of Metabolic Disorder Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Metabolic Disorder Therapeutics Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by By Product
  • Market Attractiveness Analysis by By Disease
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Metabolic Disorder Therapeutics Market Analysis by By Product (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Metachromatic Leukodystrophy by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Globoid Leukodystrophy by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Hepatic Encephalopathy by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Others by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis by By Disease (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Diabetes by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Obesity by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Hypercholesterolemia by Geography (USD MN)
  • Global Metabolic Disorder Therapeutics Market Analysis in Lysosomal Storage Diseases by Geography (USD MN)
  • Latin America Metabolic Disorder Therapeutics Market by Revenue
  • Middle East & Africa Metabolic Disorder Therapeutics Market by Revenue
  • Recent Development in Metabolic Disorder Therapeutics Industry
  • Company Market Share Analysis, 2019
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
目次

Value Market Research's latest report on the Global Metabolic Disorder Therapeutics Market identified a significant growth in the industry over the last few years and anticipates it to grow considerably within the forecast period of 2020-2026.

The global metabolic disorder therapeutics market report provides a complete evaluation of the market for the forecast period. The report consists of various segments as well as an analysis of the factors playing a significant role in the market. The factors include the drivers, restraints, challenges and opportunities and the impact of these factors on the market has been provided in the report. The drivers and restraints are classified as intrinsic factors while the opportunities and challenges are classified as extrinsic factors of the market. The global metabolic disorder therapeutics market study provides an insight on the developments of the market in terms of revenue throughout the specified period.

This report provides a complete analysis for the global metabolic disorder therapeutics market. An in-depth secondary research, primary interviews and in-house expert reviews are responsible for providing the market estimates for the global metabolic disorder therapeutics market. These market estimates have been put together by studying the impact of different social, political and economic factors along with the current market dynamics that are affecting the global metabolic disorder therapeutics market growth.

The report begins with the market overview, followed by a crisp executive summary. The Porter's Five Forces analysis covered in this study will assist in understanding the five forces namely buyers bargaining power, suppliers bargaining power, threat of new entrants, the threat of substitutes and the degree of competition in the global metabolic disorder therapeutics market. It also helps to explain the various participants such as system integrators, intermediaries and end users within the market. The report by Value Market Research also focuses on the competitive landscape of the global metabolic disorder therapeutics market.

The market analysis involves a section exclusively to list the major players of the global metabolic disorder therapeutics market wherein our analysts provide an insight into the financial statements of all the key players along with its key development product. The company profile section in the report also provides a business overview and financial information. The companies provided in this section can be customized as per the client's requirement.

The Metabolic Disorder Therapeutics Market Report Segments the market as below -

By Product

Metachromatic Leukodystrophy

Globoid Leukodystrophy

Hepatic Encephalopathy

Others

By Disease

Diabetes

Obesity

Hypercholesterolemia

Lysosomal Storage Diseases

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Metabolic Disorder Therapeutics Market
  • 2.2. Global Metabolic Disorder Therapeutics Market Snapshot

3 . METABOLIC DISORDER THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction
  • 3.2. Market Drivers of Metabolic Disorder Therapeutics Market
  • 3.3. Market Restraints of Metabolic Disorder Therapeutics Market
  • 3.4. Opportunities of Metabolic Disorder Therapeutics Market
  • 3.5. Trends of Metabolic Disorder Therapeutics Market
  • 3.6. Porter's Five Force Analysis of Metabolic Disorder Therapeutics Market
  • 3.7. Metabolic Disorder Therapeutics Market Attractiveness Analysis
    • 3.7.1 Market Attractive Analysis by By Product
    • 3.7.2 Market Attractive Analysis by By Disease
    • 3.7.3 Market Attractive Analysis by Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Metabolic Disorder Therapeutics Value Chain Analysis
  • 4.2. Metabolic Disorder Therapeutics Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Metabolic Disorder Therapeutics Raw Material Manufactures List
    • 4.2.3. Price Trend of Metabolic Disorder Therapeutics Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET ANALYSIS BY BY PRODUCT

  • 5.1 Overview by By Product
  • 5.2 Global Metabolic Disorder Therapeutics Market Analysis by By Product
  • 5.3 Market Analysis of Metachromatic Leukodystrophy by Regions
  • 5.4 Market Analysis of Globoid Leukodystrophy by Regions
  • 5.5 Market Analysis of Hepatic Encephalopathy by Regions
  • 5.6 Market Analysis of Others by Regions

6 . GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET ANALYSIS BY BY DISEASE

  • 6.1 Overview by By Disease
  • 6.2 Global Metabolic Disorder Therapeutics Market Analysis by By Disease
  • 6.3 Market Analysis of Diabetes by Regions
  • 6.4 Market Analysis of Obesity by Regions
  • 6.5 Market Analysis of Hypercholesterolemia by Regions
  • 6.6 Market Analysis of Lysosomal Storage Diseases by Regions

7 . GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America
    • 7.3.1. Overview
    • 7.3.2. North America Metabolic Disorder Therapeutics Market Estimate by Market Segment
    • 7.3.3. North America Metabolic Disorder Therapeutics Market Estimate by Country
    • 7.3.4. United State
    • 7.3.5. Rest of North America
  • 7.4. Europe
    • 7.4.1. Overview
    • 7.4.2. Europe Metabolic Disorder Therapeutics Market Estimate by Market Segment
    • 7.4.3. Europe Metabolic Disorder Therapeutics Market Estimate by Country
    • 7.4.4. United Kingdom
    • 7.4.5. France
    • 7.4.6. Germany
    • 7.4.7 Rest of Europe
  • 7.5. Asia Pacific
    • 7.5.1. Overview
    • 7.5.2. Asia Pacific Metabolic Disorder Therapeutics Market Estimate by Market Segment
    • 7.5.3. Asia Pacific Metabolic Disorder Therapeutics Market Estimate by Country
    • 7.5.4. China
    • 7.5.5. Japan
    • 7.5.6. India
    • 7.5.7. Rest of Asia Pacific
  • 7.6. Latin America
    • 7.6.1. Overview
    • 7.6.2. Latin America Metabolic Disorder Therapeutics Market Estimate by Market Segment
    • 7.6.3. Latin America Metabolic Disorder Therapeutics Market Estimate by Country
    • 7.6.4. Brazil
    • 7.6.5. Rest of Latin America
  • 7.7. Middle East & Africa
    • 7.7.1. Overview
    • 7.7.2. Middle East & Africa Metabolic Disorder Therapeutics Market Estimate by Market Segment
    • 7.7.3. Middle East & Africa Metabolic Disorder Therapeutics Market Estimate by Country
    • 7.7.4. Middle East
    • 7.7.5. Africa

8 . COMPETITIVE LANDSCAPE OF THE METABOLIC DISORDER THERAPEUTICS COMPANIES

  • 8.1. Metabolic Disorder Therapeutics Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9 . COMPANY PROFILES OF METABOLIC DISORDER THERAPEUTICS INDUSTRY

  • 9.1. Company Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. AbbVie Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financials
    • 9.3.3. Products
    • 9.3.4. Recent Developments
  • 9.4. Actelion Pharmaceuticals Ltd.
    • 9.4.1. Company Overview
    • 9.4.2. Financials
    • 9.4.3. Products
    • 9.4.4. Recent Developments
  • 9.5. AstraZeneca
    • 9.5.1. Company Overview
    • 9.5.2. Financials
    • 9.5.3. Products
    • 9.5.4. Recent Developments
  • 9.6. Biocon
    • 9.6.1. Company Overview
    • 9.6.2. Financials
    • 9.6.3. Products
    • 9.6.4. Recent Developments
  • 9.7. Boehringer Ingelheim
    • 9.7.1. Company Overview
    • 9.7.2. Financials
    • 9.7.3. Products
    • 9.7.4. Recent Developments
  • 9.8. CymaBay Therapeutics
    • 9.8.1. Company Overview
    • 9.8.2. Financials
    • 9.8.3. Products
    • 9.8.4. Recent Developments
  • 9.9. Eli Lilly and Company
    • 9.9.1. Company Overview
    • 9.9.2. Financials
    • 9.9.3. Products
    • 9.9.4. Recent Developments
  • 9.10. Merck KgaA
    • 9.10.1. Company Overview
    • 9.10.2. Financials
    • 9.10.3. Products
    • 9.10.4. Recent Developments
  • 9.11. Novo Nordisk
    • 9.11.1. Company Overview
    • 9.11.2. Financials
    • 9.11.3. Products
    • 9.11.4. Recent Developments
  • 9.12. Sanofi
    • 9.12.1. Company Overview
    • 9.12.2. Financials
    • 9.12.3. Products
    • 9.12.4. Recent Developments

10. IMPACT ANALYSIS OF COVID-19 OUTBREAK

  • 10.1. Impact Analysis of Covid-19 Outbreak on the Market
    • 10.1.1. Direct Impact on Production
    • 10.1.2. Supply Chain and Market Disruption
    • 10.1.3. Financial Impact on Firms and Financial Markets
  • 10.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
  • 10.3. Pre V/S Post COVID-19 Market
  • 10.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Market Size in 2020, by Scenario
  • 10.5. COVID-19: Micro and Macro Factor Analysis on the Market

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.